These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 27614845)

  • 1. Transgenic T cell-specific expression of CXCR3 enhances splenic and hepatic T cell accumulation but does not affect the outcome of visceral leishmaniasis.
    Varikuti S; Natarajan G; Oghumu S; Sperling RH; Moretti E; Stock J; Papenfuss TL; Satoskar AR
    Cell Immunol; 2016 Nov; 309():61-68. PubMed ID: 27614845
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The IL-33/ST2 axis is associated with human visceral leishmaniasis and suppresses Th1 responses in the livers of BALB/c mice infected with Leishmania donovani.
    Rostan O; Gangneux JP; Piquet-Pellorce C; Manuel C; McKenzie AN; Guiguen C; Samson M; Robert-Gangneux F
    mBio; 2013 Sep; 4(5):e00383-13. PubMed ID: 24045639
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transgenic expression of CXCR3 on T cells enhances susceptibility to cutaneous Leishmania major infection by inhibiting monocyte maturation and promoting a Th2 response.
    Oghumu S; Stock JC; Varikuti S; Dong R; Terrazas C; Edwards JA; Rappleye CA; Holovatyk A; Sharpe A; Satoskar AR
    Infect Immun; 2015 Jan; 83(1):67-76. PubMed ID: 25312956
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lack of CXCR3 delays the development of hepatic inflammation but does not impair resistance to Leishmania donovani.
    Barbi J; Oghumu S; Rosas LE; Carlson T; Lu B; Gerard C; Lezama-Davila CM; Satoskar AR
    J Infect Dis; 2007 Jun; 195(11):1713-7. PubMed ID: 17471442
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Live Attenuated Leishmania donovani Centrin Knock Out Parasites Generate Non-inferior Protective Immune Response in Aged Mice against Visceral Leishmaniasis.
    Bhattacharya P; Dey R; Dagur PK; Joshi AB; Ismail N; Gannavaram S; Debrabant A; Akue AD; KuKuruga MA; Selvapandiyan A; McCoy JP; Nakhasi HL
    PLoS Negl Trop Dis; 2016 Aug; 10(8):e0004963. PubMed ID: 27580076
    [TBL] [Abstract][Full Text] [Related]  

  • 6. IL-17A promotes susceptibility during experimental visceral leishmaniasis caused by Leishmania donovani.
    Terrazas C; Varikuti S; Kimble J; Moretti E; Boyaka PN; Satoskar AR
    FASEB J; 2016 Mar; 30(3):1135-43. PubMed ID: 26581600
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Induction of host protective Th1 immune response by chemokines in Leishmania donovani-infected BALB/c mice.
    Dey R; Majumder N; Bhattacharyya Majumdar S; Bhattacharjee S; Banerjee S; Roy S; Majumdar S
    Scand J Immunol; 2007 Dec; 66(6):671-83. PubMed ID: 18021365
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A mixed Th1/Th2 response elicited by a liposomal formulation of Leishmania vaccine instructs Th1 responses and resistance to Leishmania donovani in susceptible BALB/c mice.
    Mazumdar T; Anam K; Ali N
    Vaccine; 2004 Mar; 22(9-10):1162-71. PubMed ID: 15003644
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hybrid cell vaccination resolves Leishmania donovani infection by eliciting a strong CD8+ cytotoxic T-lymphocyte response with concomitant suppression of interleukin-10 (IL-10) but not IL-4 or IL-13.
    Basu R; Bhaumik S; Haldar AK; Naskar K; De T; Dana SK; Walden P; Roy S
    Infect Immun; 2007 Dec; 75(12):5956-66. PubMed ID: 17908806
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interleukin-7 potentiates MAPK10-elicited host-protective vaccine against Leishmania donovani.
    Kumar S; Bodhale N; Patra SK; Sarode A; Zhao L; Sarkar A; Saha B
    Cytokine; 2024 Feb; 174():156475. PubMed ID: 38134556
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neutralization of IL-12 demonstrates the existence of discrete organ-specific phases in the control of Leishmania donovani.
    Engwerda CR; Murphy ML; Cotterell SE; Smelt SC; Kaye PM
    Eur J Immunol; 1998 Feb; 28(2):669-80. PubMed ID: 9521077
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tissue requirements for establishing long-term CD4+ T cell-mediated immunity following Leishmania donovani infection.
    Bunn PT; Stanley AC; de Labastida Rivera F; Mulherin A; Sheel M; Alexander CE; Faleiro RJ; Amante FH; Montes De Oca M; Best SE; James KR; Kaye PM; Haque A; Engwerda CR
    J Immunol; 2014 Apr; 192(8):3709-18. PubMed ID: 24634490
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunotherapeutic Potential of Eugenol Emulsion in Experimental Visceral Leishmaniasis.
    Islamuddin M; Chouhan G; Want MY; Ozbak HA; Hemeg HA; Afrin F
    PLoS Negl Trop Dis; 2016 Oct; 10(10):e0005011. PubMed ID: 27776125
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Involvement of CD4⁺ Foxp3⁺ regulatory T cells in persistence of Leishmania donovani in the liver of alymphoplastic aly/aly mice.
    Tiwananthagorn S; Iwabuchi K; Ato M; Sakurai T; Kato H; Katakura K
    PLoS Negl Trop Dis; 2012; 6(8):e1798. PubMed ID: 22928057
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Critical role of IRF-5 in the development of T helper 1 responses to Leishmania donovani infection.
    Paun A; Bankoti R; Joshi T; Pitha PM; Stäger S
    PLoS Pathog; 2011 Jan; 7(1):e1001246. PubMed ID: 21253574
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The capacity to produce IFN-gamma rather than the presence of interleukin-4 determines the resistance and the degree of susceptibility to Leishmania donovani infection in mice.
    Lehmann J; Enssle KH; Lehmann I; Emmendörfer A; Lohmann-Matthes ML
    J Interferon Cytokine Res; 2000 Jan; 20(1):63-77. PubMed ID: 10670653
    [TBL] [Abstract][Full Text] [Related]  

  • 17. gp63 in stable cationic liposomes confers sustained vaccine immunity to susceptible BALB/c mice infected with Leishmania donovani.
    Bhowmick S; Ravindran R; Ali N
    Infect Immun; 2008 Mar; 76(3):1003-15. PubMed ID: 18195029
    [TBL] [Abstract][Full Text] [Related]  

  • 18. STAT4 is critical for immunity but not for antileishmanial activity of antimonials in experimental visceral leishmaniasis.
    Oghumu S; Gupta G; Snider HM; Varikuti S; Terrazas CA; Papenfuss TL; Kaplan MH; Satoskar AR
    Eur J Immunol; 2014 Feb; 44(2):450-9. PubMed ID: 24242758
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 115 kDa serine protease confers sustained protection to visceral leishmaniasis caused by Leishmania donovani via IFN-γ induced down-regulation of TNF-α mediated MMP-9 activity.
    Choudhury R; Das P; De T; Chakraborti T
    Immunobiology; 2013 Jan; 218(1):114-26. PubMed ID: 22440312
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Complete protection against experimental visceral leishmaniasis with complete soluble antigen from attenuated Leishmania donovani promastigotes involves Th1-immunity and down-regulation of IL-10.
    Bhaumik SK; Naskar K; De T
    Eur J Immunol; 2009 Aug; 39(8):2146-60. PubMed ID: 19593771
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.